ProfileGDS5678 / 1439466_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 96% 96% 96% 96% 97% 95% 94% 95% 95% 96% 96% 96% 96% 96% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.7421696
GSM967853U87-EV human glioblastoma xenograft - Control 28.9786596
GSM967854U87-EV human glioblastoma xenograft - Control 38.9680796
GSM967855U87-EV human glioblastoma xenograft - Control 48.9546996
GSM967856U87-EV human glioblastoma xenograft - Control 59.1929297
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.2570895
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.0534494
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.5663395
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.5776995
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.8494396
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.6860896
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 39.0345196
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.8659196
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 59.0410696